Zhejiang CONBA Pharmaceutical Co.,Ltd. Stock price

Equities

600572

CNE000001H86

Pharmaceuticals

End-of-day quote Shanghai S.E. 07:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
4.81 CNY +1.05% Intraday chart for Zhejiang CONBA Pharmaceutical Co.,Ltd. -3.61% -4.75%
Sales 2023 * 6.94B 962M Sales 2024 * 8.05B 1.11B Capitalization 12.36B 1.71B
Net income 2023 * 640M 88.65M Net income 2024 * 810M 112M EV / Sales 2023 * 1.78 x
Net cash position 2023 * - 0 Net cash position 2024 * - 0 EV / Sales 2024 * 1.54 x
P/E ratio 2023 *
19.5 x
P/E ratio 2024 *
15.2 x
Employees 8,415
Yield 2023 *
2.49%
Yield 2024 *
2.91%
Free-Float 59.66%
More Fundamentals * Assessed data
Dynamic Chart
Shanghai-Listed Firms Actively Repurchase Shares as Regulators Focus on Market Value MT
Shanghai Dingjia Trading Co., Ltd. agreed to acquire 20% stake in Shanghai Kede Network Technology Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd. for CNY 26 million. CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. announces an Equity Buyback for CNY 400 million worth of its shares. CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. authorizes a Buyback Plan. CI
CONBA Pharma Gets Nod to Trial Cough Medicine MT
CONBA Pharma Unit's Acetyl Cysteine Granules Chosen for China's Centralized Drug Procurement MT
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) added to S&P Global BMI Index CI
Zhejiang CONBA Pharmaceutical Co.,Ltd.(XSSC:600572) added to FTSE All-World Index CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) completed the acquisition of 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd. CI
CONBA Pharma Gets Drug Registration for Risperidone Oral Solution MT
Wuxi China Life Chengda Equity Investment Center (Limited Partnership) and Jinhua Future Yicai Phase I Equity Investment Partnership (Limited Partnership) intends to acquire 7.84% stake in Jiangxi Zhenshiming Pharmaceutical Co., Ltd. from Zhejiang CONBA Pharmaceutical Co.,Ltd for CNY 290 million. CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Zhejiang CONBA Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
More news
1 day+1.05%
1 week-3.61%
Current month-1.64%
1 month-0.21%
3 months-4.18%
6 months-14.87%
Current year-4.75%
More quotes
1 week
4.74
Extreme 4.74
4.93
1 month
4.74
Extreme 4.74
5.08
Current year
4.07
Extreme 4.07
5.29
1 year
4.07
Extreme 4.07
7.44
3 years
3.83
Extreme 3.83
7.44
5 years
3.83
Extreme 3.83
11.26
10 years
3.83
Extreme 3.83
13.19
More quotes
Managers TitleAgeSince
President 62 20-07-21
Director of Finance/CFO 48 20-07-21
Director/Board Member 48 18-04-25
Members of the board TitleAgeSince
Chairman 63 05-04-28
Director of Finance/CFO 48 20-07-21
Director/Board Member 54 20-07-21
More insiders
Date Price Change Volume
24-03-28 4.81 +1.05% 22,339,850
24-03-27 4.76 -1.24% 23,168,100
24-03-26 4.82 -0.41% 24,463,500
24-03-25 4.84 -0.82% 25,872,920
24-03-22 4.88 -2.20% 34,042,360

End-of-day quote Shanghai S.E., March 27, 2024

More quotes
Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company, principally engaged in the research and development, manufacture and distribution of traditional Chinese medicines, modern phytomedicines and chemical drugs. The Company also provides active ingredients. The Company's products include tablets, capsules, pills, granules, powders, injections, oral solutions, syrups, eye drops, nasal drops, ear drops, ointments and others. Its products are applied in cardiovascular and cerebrovascular diseases, urinary system diseases, digestive diseases, respiratory diseases, endocrine system, nervous system, anti-infection and other treatment areas. The Company also provides value-added services. The Company distributes its products within domestic markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
4.81
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Zhejiang CONBA Pharmaceutical Co.,Ltd. - Shanghai S.E.